Rhelion ships PEX010 for Phase 3 microdose psilocybin trial
Filament delivered PEX010 to Bruyère Health Research Institute for a Phase 3, placebo-controlled microdose psilocybin trial in palliative care across seven Canadian sites.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.